Letter to the Editor: Reconsidering the routine use of adjuvant somatostatin analogs in type I gastric neuroendocrine tumors after endoscopic treatment
World Journal of Gastroenterology, cilt.32, sa.36, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 36
- Basım Tarihi: 2026
- Doi Numarası: 10.3748/wjg.120316
- Dergi Adı: World Journal of Gastroenterology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Anahtar Kelimeler: Prognosis, Side effects, Somatostatin analog, Type I gastric neuroendocrine tumor
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ankara Üniversitesi Adresli: Evet
Özet
Yang et al recently published an article in World Journal of Gastroenterology reported that adjuvant somatostatin analog (SSA) therapy following endoscopic treatment significantly reduced the risk of tumor progression in patients with type I gastric neuroendocrine tumors (G-NETs). While these findings suggest a potential therapeutic benefit, several methodological and clinical considerations require clarification before routine use of adjuvant SSA can be endorsed. Differences in follow-up times between progressive and non-progressive groups could lead to inaccurate conclusions on progression-free survival, warranting further confirmation, particularly for indolent tumors prone to late recurrence. Moreover, well-differentiated grade 1 type I G-NETs are characterized by low metastatic potential and excellent survival, and current guidelines primarily recommend SSA therapy for unresectable, recurrent, or metastatic disease. Importantly, the study did not comprehensively report distant metastases or long-term survival outcomes, limiting the assessment of clinically meaningful benefit. Furthermore, the safety profile of prolonged SSA therapy warrants careful consideration in this favorable-risk population. These issues should be addressed before routine adjuvant SSA therapy is broadly adopted.